Prosecution Insights
Last updated: May 29, 2026

Nxera Pharma UK Limited

9 pending office actions • 6 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
7
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

6
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (6)Due ≤ 30 days (1)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (22%)
7
Easy (78%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (22%)
§112 only7 (78%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

9
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BOWLES, DAVID PAUL 2 75.0% +17.5%
HSU, GRACE CHING 1 75.6% +28.6%
MOTEVALLI, OROD 1
HAVLIN, ROBERT H 1 52.3% +27.2%
LI, RUIXIANG 1 59.4% +19.0%
COFFA, SERGIO 1 61.0% +33.3%
KATAKAM, SUDHAKAR 1 75.0% +23.0%
PAK, MICHAEL D 1 58.2% +30.6%

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18304801 MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM LI, RUIXIANG 74d overdue
17909805 ORAL GLP RECEPTOR AGONISTS BOWLES, DAVID PAUL 73d overdue
17107617 METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS PAK, MICHAEL D 73d overdue
18258065 SARS-COV-2 MPRO INHIBITOR COMPOUNDS HAVLIN, ROBERT H 25d overdue
17909907 GLP RECEPTOR AGONISTS BOWLES, DAVID PAUL 10d overdue
18031416 LINEAR APELIN RECEPTOR AGONISTS COFFA, SERGIO 20d
18556178 GPR35 Agonist Compounds HSU, GRACE CHING 34d
18017693 GLP-1 RECEPTOR ANTAGONISTS KATAKAM, SUDHAKAR 63d

Top Art Units

Art UnitApps
1674 2
1658 2
1654 2
1627 1
1628 1
1626 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18556178 GPR35 Agonist Compounds HSU, GRACE CHING 1627 §112 Non-Final OA 34d Pending Oct 19, 2023
18280611 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR DEMENTIA MOTEVALLI, OROD 1628 §103 Non-Final OA 35d overdue Pending Sep 06, 2023
18258065 SARS-COV-2 MPRO INHIBITOR COMPOUNDS HAVLIN, ROBERT H 1626 §103 Non-Final OA 25d overdue Pending Jun 16, 2023
18304801 MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM LI, RUIXIANG 1674 §112 Final Rejection 74d overdue Pending Apr 21, 2023
18031416 LINEAR APELIN RECEPTOR AGONISTS COFFA, SERGIO 1658 §112 Non-Final OA 20d Pending Apr 12, 2023
18017693 GLP-1 RECEPTOR ANTAGONISTS KATAKAM, SUDHAKAR 1658 §112 Non-Final OA 63d Pending Jan 24, 2023
17909805 ORAL GLP RECEPTOR AGONISTS BOWLES, DAVID PAUL 1654 §112 Non-Final OA 73d overdue Pending Sep 07, 2022
17909907 GLP RECEPTOR AGONISTS BOWLES, DAVID PAUL 1654 §112 Non-Final OA 10d overdue Pending Sep 07, 2022
17107617 METHODS FOR SCREENING FOR BINDING PARTNERS OF G-PROTEIN COUPLED RECEPTORS PAK, MICHAEL D 1674 §112 Final Rejection 73d overdue Pending Nov 30, 2020

Managing Nxera Pharma UK Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month